The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2023 | REFRACT: standard chemoimmunotherapy versus novel agents in R/R follicular lymphoma
Kim Linton, MBChB, MRCP, PhD, FRCP, University of Manchester and The Christie NHS Foundation Trust, Manchester, UK, shares some insights into the Phase II NCRI investigator-led REFRACT trial, which will evaluate novel therapies versus standard of care (SOC) chemoimmunotherapy in patients with relapsed/refractory (R/R) follicular lymphoma (FL). Dr Linton highlights the various treatment arms being evaluated, and further explains that this trial will investigate potential novel biomarkers for early relapse and resistance to therapy. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Dr Linton has done external consultancy for Genmab, Abbvie and Beigene and has received research funding to institution from Abbvie and Genmab.
